Venture Life Group PLC Two new CE Mark approvals (4578F)
18 May 2017 - 4:00PM
UK Regulatory
TIDMVLG
RNS Number : 4578F
Venture Life Group PLC
18 May 2017
Venture Life Group plc
("Venture Life" or the "Company")
Two New CE Mark Approvals
Venture Life (AIM: VLG), the international consumer self-care
group focused on developing, manufacturing and commercialising
products for the ageing population, announces that two of its new
medical device products, Myco-Clear and Rosacalma, have received CE
Mark regulatory approval, enabling both products to be marketed and
sold as medical devices within the EU.
Myco-Clear is a topical product for the treatment of
Onychomicosis (a fungal nail infection). This condition causes the
unsightly discolouration and distortion of finger and toe nails. It
can affect patients as they age and is exacerbated by
immunodeficiency disorders, immunomodulating and immunosuppressing
drugs and sports activities. Myco-Clear treats the condition and
rapidly improves the appearance of the nail through an easily
applied and absorbed once daily topical treatment.
Rosacalma is a complete treatment portfolio for managing the
symptoms of Rosacea, an inflammatory skin disease causing facial
redness. Rosacea affects 10% of the general population between
30-50 years of age. Rosacalma is milder than existing treatments,
and is therefore more gentle on the skin and can be used for a much
longer period than other usual treatments. There are three products
within the Rosacalma range - a cleanser, a day cream and night
serum; all three products were developed in-house and are now ready
to be marketed and sold. Both Myco-Clear and Rosacalma will now be
presented to potential international distribution partners during
2017, ready for launch in 2018 and beyond.
Jerry Randall, CEO of Venture Life, commented: "The CE Mark
approval for Myco-Clear and Rosacalma in Europe is a significant
accomplishment that validates these innovative new products. There
is significant unmet need for these products, which we have
developed in-house. 2016 was a landmark year for Venture Life which
saw 57% revenue growth, further brand development and brand
launches. We are now focused on driving new business through new
and existing markets via science, technology and innovation as well
as growing our core business portfolio."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
For further information please contact:
+44 (0) 1344
Venture Life Group PLC 742870
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited +44 (0) 20
(Nominated Adviser and Joint Broker) 3861 6625
Matthew Johnson / Edward Hutton / Margarita
Mitropoulou (Corporate Finance)
Bob Pountney / John Howes (Corporate
Broking)
Turner Pope Investments (TPI) Ltd (Joint +44 (0) 20
Broker) 3621 4120
James Pope / Ben Turner
Walbrook PR venturelife@walbrookpr.com
or + 44 (0) 20 7933 8780
Paul McManus / Anna Dunphy +44 (0) 7980 541 893 / +44
(0) 7876 741 001
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the ageing population. The Group's product portfolio includes
some key products such as the UltraDEX oral care products range,
food supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
haemorrhoids and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
REASFMFLWFWSEDI
(END) Dow Jones Newswires
May 18, 2017 02:00 ET (06:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024